Archer Aviation Inc vs CVS Health Corp — how do they compare? Archer Aviation Inc trades at $6.81 (market cap $4.78B), while CVS Health Corp trades at $93.7 (market cap $122.36B). The key difference: CVS Health Corp is far larger — about 25.6× Archer Aviation Inc's market cap, and CVS Health Corp pays a 2.78% dividend while Archer Aviation Inc pays none. Which is the better fit depends on your goals.
| ACHR | CVS | |
|---|---|---|
Market Cap | $4.78B | $122.36B |
Sector | Industrials | Health |
52-Week High | $13.64 | $110.60 |
52-Week Low | $4.44 | $65.51 |
Enterprise Value | $3.12B | $184.71B |
Dividend Yield | — | 2.78% |
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $5.59, up 6.88% today, with a bullish technical signal from moving averages. The company reported a Q2 2026 loss of $0.34 per share, missing estimates, but revenue trends show growth from $300,000 in 2025 to $2 million in 2026. Recent news highlights a transformative deal with Boeing to acquire Wisk Aero, Insitu, and SkyGrid, expanding into autonomous aviation and defense, which spurred a stock surge and high options trading activity.
The outlook is optimistic due to strategic expansion and strong analyst support, with 78% buy ratings and a 78.7% upside price target. However, risks include persistent losses, negative cash flow from operations, and execution challenges in scaling new businesses, requiring careful monitoring of profitability milestones.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Trailing returns across standard periods
Latest headlines on both assets
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →